Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza: a randomized controlled trial. US Oral Neuraminidase Study Group - PubMed (original) (raw)
Clinical Trial
. 2000 Feb 23;283(8):1016-24.
doi: 10.1001/jama.283.8.1016.
Affiliations
- PMID: 10697061
- DOI: 10.1001/jama.283.8.1016
Clinical Trial
Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza: a randomized controlled trial. US Oral Neuraminidase Study Group
J J Treanor et al. JAMA. 2000.
Abstract
Context: Previous studies have shown oseltamivir, a neuraminidase inhibitor, to be effective in preventing influenza and treating experimental influenza.
Objective: To evaluate the efficacy and safety of oseltamivir in the treatment of naturally acquired influenza infection.
Design: Randomized, placebo-controlled, double-blind study conducted January through March 1998.
Setting: Sixty primary care and university health centers throughout the United States.
Participants: A total of 629 healthy nonimmunized adults aged 18 to 65 years with febrile respiratory illness of no more than 36 hours' duration with temperature of 38 degrees C or more plus at least 1 respiratory symptom and 1 constitutional symptom.
Interventions: Individuals were randomized to 1 of 3 treatment groups with identical appearing pills: oral oseltamivir phosphate, 75 mg twice daily (n = 211) or 150 mg (n = 209) twice daily, or placebo (n = 209).
Main outcome measures: Duration and severity of illness in individuals infected with influenza.
Results: Two individuals withdrew before receiving medication and were excluded from further analyses. A total of 374 individuals (59.6%) were infected with influenza. Their duration of illness was reduced by more than 30% with both oseltamivir, 75 mg twice daily (median, 71.5 hours; P < .001), and oseltamivir, 150 mg twice daily (median, 69.9 hours; P = .006), compared with placebo (median, 103.3 hours). Severity of illness was reduced by 38% (median score, 597 score-hours; P < .001) with oseltamivir, 75 mg twice daily, and by 35% (median score, 626 score-hours; P < .001) with oseltamivir, 150 mg twice daily, vs placebo (median score, 963 score-hours). Oseltamivir treatment reduced the duration of fever and oseltamivir recipients returned to usual activities 2 to 3 days earlier than placebo recipients (P < or = .05). Secondary complications such as bronchitis and sinusitis occurred in 15% of placebo recipients compared with 7% of combined oseltamivir recipients (P = .03). Among all 629 subjects, oseltamivir reduced illness duration (76.3 hours and 74.3 hours for 75 mg and 150 mg, respectively, vs 97.0 hours for placebo; P = .004 for both comparisons) and illness severity (686 score-hours and 629 score-hours for 75 mg and 150 mg, respectively, vs 887 score-hours for placebo; P < .001 for both comparisons). Nausea and vomiting occurred more frequently in both oseltamivir groups (combined, 18.0% and 14.1%, respectively; P = .002) than in the placebo group (7.4% and 3.4%; P < .001).
Conclusions: Our data suggest that oral oseltamivir treatment reduces the duration and severity of acute influenza in healthy adults and may decrease the incidence of secondary complications.
Comment in
- Expanding the treatment options for influenza.
Wenzel RP. Wenzel RP. JAMA. 2000 Feb 23;283(8):1057-9. doi: 10.1001/jama.283.8.1057. JAMA. 2000. PMID: 10697068 No abstract available.
Similar articles
- Use of the oral neuraminidase inhibitor oseltamivir in experimental human influenza: randomized controlled trials for prevention and treatment.
Hayden FG, Treanor JJ, Fritz RS, Lobo M, Betts RF, Miller M, Kinnersley N, Mills RG, Ward P, Straus SE. Hayden FG, et al. JAMA. 1999 Oct 6;282(13):1240-6. doi: 10.1001/jama.282.13.1240. JAMA. 1999. PMID: 10517426 Clinical Trial. - A double-blind, randomized, placebo-controlled multicenter study of oseltamivir phosphate for treatment of influenza infection in China.
Li L, Cai B, Wang M, Zhu Y. Li L, et al. Chin Med J (Engl). 2003 Jan;116(1):44-8. doi: 10.3901/jme.2003.06.044. Chin Med J (Engl). 2003. PMID: 12667386 Clinical Trial. - [A multicenter study of efficacy and safety of oseltamivir in treatment of naturally acquired influenza].
Li L, Cai B, Wang M, Zhu Y. Li L, et al. Zhonghua Nei Ke Za Zhi. 2001 Dec;40(12):838-42. Zhonghua Nei Ke Za Zhi. 2001. PMID: 16206676 Clinical Trial. Chinese. - Oseltamivir: a review of its use in influenza.
McClellan K, Perry CM. McClellan K, et al. Drugs. 2001;61(2):263-83. doi: 10.2165/00003495-200161020-00011. Drugs. 2001. PMID: 11270942 Review. - Neuraminidase inhibitors for preventing and treating influenza in children.
Wang K, Shun-Shin M, Gill P, Perera R, Harnden A. Wang K, et al. Cochrane Database Syst Rev. 2012 Jan 18;1:CD002744. doi: 10.1002/14651858.CD002744.pub3. Cochrane Database Syst Rev. 2012. PMID: 22258949 Updated. Review.
Cited by
- Safety analysis of Oseltamivir and Baloxavir Marboxil after market approval: a pharmacovigilance study based on the FDA adverse event reporting system.
Li Y, Wang X, Liao Y, Zeng Y, Lin W, Zhuang W. Li Y, et al. BMC Infect Dis. 2024 May 9;24(1):446. doi: 10.1186/s12879-024-09339-4. BMC Infect Dis. 2024. PMID: 38724914 Free PMC article. - Synthesis of Rupestonic Acid L-Ephedrine Derivatives with Preliminary In vitro Anti-influenza Viral Activity.
Yong J, Lu C. Yong J, et al. Curr Pharm Des. 2024;30(18):1398-1403. doi: 10.2174/0113816128282194240329045625. Curr Pharm Des. 2024. PMID: 38623973 - The Role and Value of Professional Rapid Testing of Acute Respiratory Infections (ARIs) in Europe: A Special Focus on the Czech Republic, Poland, and Romania.
Drevinek P, Flisiak R, Nemes R, Nogales Crespo KA, Tomasiewicz K. Drevinek P, et al. Diagnostics (Basel). 2024 Mar 16;14(6):631. doi: 10.3390/diagnostics14060631. Diagnostics (Basel). 2024. PMID: 38535051 Free PMC article. Review. - Antiviral options and therapeutics against influenza: history, latest developments and future prospects.
Meseko C, Sanicas M, Asha K, Sulaiman L, Kumar B. Meseko C, et al. Front Cell Infect Microbiol. 2023 Nov 29;13:1269344. doi: 10.3389/fcimb.2023.1269344. eCollection 2023. Front Cell Infect Microbiol. 2023. PMID: 38094741 Free PMC article. Review. - Safety, tolerability, and pharmacokinetics of TG-1000, a new molecular entity against influenza virus: first-in-human study.
Xu SM, Chang LW, Tsai CY, Liu WL, Li D, Li SS, Li XM, Xu PS. Xu SM, et al. Front Pharmacol. 2023 Nov 1;14:1272466. doi: 10.3389/fphar.2023.1272466. eCollection 2023. Front Pharmacol. 2023. PMID: 38027026 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical